Back to News
Press Release

Centers for Dialysis Care Signs Deal to Offer Non-Invasive Cardiovascular Monitoring to Patients in Northeast Ohio

 

Multi-Year deal provides Centers for Dialysis Care a first-mover advantage by adopting non-invasive cardiovascular solution for dialysis – CVInsight™ by InteloMed

 

Shaker Heights, OH October 21, 2015 – Centers for Dialysis Care (CDC), Northeast Ohio’s largest dialysis provider, is the first dialysis group to implement next-generation non-invasive cardiovascular monitoring in the state of Ohio.  The multi-year contract with InteloMed, Inc., allows for the deployment of the CVInsight™ Platform to multiple CDC facilities system-wide over the next two years to better serve patients.

 

The CVInsight™ Platform is an easy-to-use system that provides clinicians with non-invasive, real-time, dynamic and actionable information about a patient’s cardiovascular stability.  A non-invasive sensor is worn by the dialysis patient in order to monitor the patient’s tolerance to the treatment.  The system alerts and provides indications to clinical staff members, allowing them to intervene and make adjustments during therapy.

 

“CVInsight™ has proven itself to be a valuable new tool for assessing patient stability during dialysis.  The additional information provided about patient tolerance to treatment has allowed CDC to be more confident in treating patients and achieve our fluid removal goals,” said Peter DeOreo, MD and Chief Medical Officer for Centers for Dialysis Care.

 

The rate of fluid removal during dialysis treatment can be one of the leading causes of intradialytic hypotensive events.  Intradialytic hypotensive events are a frequent complication during dialysis and are associated with negative patient outcomes.

 

“CDC is committed to achieving the very best outcomes for patients.  By embracing this tool and coupling it with standard protocols which are delivered by our empowered and effective clinical team, CVInsight™ is helping us to achieve our goals to continually improve clinical outcomes,” stated Diane Wish, President and CEO for Centers for Dialysis Care.

 

Jill Schiaparelli, President and CEO of InteloMed commented, “InteloMed is honored to collaborate with Centers for Dialysis Care, a leading provider with a strong focus on patient-centered care.  CDC’s adoption of the CVInsight™ Platform for assessing patient response to dialysis treatment confirms the need for non-invasive continuous monitoring alternatives.”

 

About Centers for Dialysis Care

The Centers for Dialysis Care (CDC) is a leader in providing patient-centered quality care to all individuals with kidney disease. For over 40 years CDC has been a non-profit independent provider of dialysis and related health services and a leading innovator providing outstanding patient-focused dialysis treatment, education support, and training. With 18 locations, across Cleveland, Mentor, Beachwood, Jefferson, Warren, Youngstown, Oakwood, Shaker Heights, Euclid, Garfield Heights and Warrensville, CDC is proud to be Northeast Ohio’s largest dialysis provider. CDC is a growing organization that rapidly responds to changes, attracts and retains quality staff, and collaborates with physicians, providers, and payors.

 

For more information, visit www.cdcare.org.

 

About InteloMed

InteloMed is redefining the standard of care in cardiovascular monitoring through its intelligent multi-dimensional, non-invasive CVInsight™ platform. The CVInsight™ platform provides real-time insights to inform clinical decisions in a variety of healthcare applications, including in-patient and out-patient facilities, clinics, medical facilities and sleep labs.

To learn more about Intelomed and CVInsight™ visit www.intelomed.com.

 

Safe Harbor Statement

Certain statements in this release are “forward-looking” and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital in order to grow our business, our ability to engage qualified employees, the acceptance of new products by doctors and hospitals, changes in the regulatory environment and healthcare legislation, the need to keep pace with technological changes, our dependence on third party manufacturers to produce components of our technology platform on time and to our specifications, and the successful implementation of our commercial strategies.

 

CONTACT

 

Company Contact:

Jim Sweeney

Chief Commercialization Officer

InteloMed, Inc.

1.855.279.0551

info@InteloMed.com

 

PR / Media Contact:

Matthew Bird

President

1-800-PublicRelations, Inc.

646.401.4499

matt.bird@1800pr.com